IBB stock forecast, quote, news & analysis

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL).

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

The average market capitalization across the iShares Biotechnology ETF ETF is 6.02B. The market cap for tickers in the group ranges from 16.97M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is MRNS at 16.97M.

The average weekly price growth across all stocks in the iShares Biotechnology ETF ETF was 92%. For the same ETF, the average monthly price growth was 230%, and the average quarterly price growth was 447%. ACRS experienced the highest price growth at 62%, while CABA experienced the biggest fall at -44%.

The average weekly volume growth across all stocks in the iShares Biotechnology ETF ETF was -9%. For the same stocks of the ETF, the average monthly volume growth was 41% and the average quarterly volume growth was 27%